Zacks Research Expects Higher Earnings for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities research analysts at Zacks Research boosted their Q1 2026 EPS estimates for Globus Medical in a note issued to investors on Monday, November 4th. Zacks Research analyst R. Department now expects that the medical device company will post earnings of $0.85 per share for the quarter, up from their prior estimate of $0.84. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2026 earnings at $1.03 EPS.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.18. The company had revenue of $625.71 million for the quarter, compared to analyst estimates of $604.69 million. Globus Medical had a net margin of 1.82% and a return on equity of 8.70%. Globus Medical’s revenue for the quarter was up 63.1% on a year-over-year basis. During the same quarter last year, the business earned $0.57 EPS.

Several other equities analysts have also weighed in on GMED. Bank of America lifted their price objective on Globus Medical from $55.00 to $80.00 and gave the company an “underperform” rating in a research note on Wednesday. Canaccord Genuity Group boosted their price objective on shares of Globus Medical from $79.00 to $85.00 and gave the stock a “buy” rating in a research note on Wednesday. Roth Mkm reissued a “buy” rating and issued a $100.00 target price on shares of Globus Medical in a research note on Wednesday. Royal Bank of Canada lifted their target price on shares of Globus Medical from $80.00 to $92.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Wells Fargo & Company increased their price target on Globus Medical from $78.00 to $88.00 and gave the company an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $87.09.

Globus Medical Trading Up 9.4 %

GMED stock opened at $82.70 on Wednesday. The company has a market cap of $11.20 billion, a PE ratio of 275.67, a price-to-earnings-growth ratio of 2.06 and a beta of 1.17. The stock has a 50-day moving average price of $71.92 and a two-hundred day moving average price of $68.16. Globus Medical has a 12-month low of $43.38 and a 12-month high of $84.87.

Insider Activity

In other Globus Medical news, Director Ann D. Rhoads sold 15,000 shares of Globus Medical stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the sale, the director now directly owns 42,884 shares in the company, valued at $3,017,318.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Globus Medical news, Director Ann D. Rhoads sold 15,000 shares of the stock in a transaction on Friday, September 13th. The shares were sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the transaction, the director now directly owns 42,884 shares in the company, valued at $3,017,318.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David D. Davidar sold 30,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $75.04, for a total transaction of $2,251,200.00. Following the completion of the sale, the director now directly owns 536,275 shares of the company’s stock, valued at $40,242,076. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 18.54% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GMED. V Square Quantitative Management LLC bought a new position in Globus Medical during the third quarter worth $27,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Globus Medical during the second quarter worth $33,000. Farther Finance Advisors LLC raised its holdings in shares of Globus Medical by 230.5% during the third quarter. Farther Finance Advisors LLC now owns 552 shares of the medical device company’s stock worth $39,000 after purchasing an additional 385 shares during the period. GAMMA Investing LLC lifted its position in shares of Globus Medical by 254.5% in the 2nd quarter. GAMMA Investing LLC now owns 631 shares of the medical device company’s stock worth $43,000 after buying an additional 453 shares during the last quarter. Finally, International Assets Investment Management LLC acquired a new position in shares of Globus Medical in the 2nd quarter valued at about $52,000. Institutional investors and hedge funds own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.